{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yamakage H"],"funding":["Smoking Research Foundation","ONO PHARMACEUTICAL CO., LTD.","Takeda Science Foundation","National Hospital Organization for collaborative clinical research","Health Science University","AstraZeneca","Japan Society for the Promotion of Science"],"pagination":["653-661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7232283"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(3)"],"pubmed_abstract":["<h4>Aims/introduction</h4>Our aims were to examine the add-on effects of a sodium-glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal muscle mass (SMM) negative regulator, myostatin; and a metabolic regulator, irisin, in patients with type 2 diabetes.<h4>Materials and methods</h4>A total of 54 patients with type 2 diabetes were randomly divided into dapagliflozin and control groups. The dapagliflozin group received dapagliflozin 5 mg/day in addition to conventional therapy for 24 weeks. The primary outcome was the change in the level of serum FGF21 from baseline. The secondary outcomes included changes from baseline in a"],"journal":["Journal of diabetes investigation"],"pubmed_title":["Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial."],"pmcid":["PMC7232283"],"funding_grant_id":["N/A","JP18H02737","JP18K19769","H26-NHO-02","JP19K07905","JP19K07927","JP19K11760","2019T004","JP17K09827"],"pubmed_authors":["Inoue T","Odori S","Yamakage H","Kusakabe T","Satoh-Asahara N","Tanaka M"],"additional_accession":[]},"is_claimable":false,"name":"Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.","description":"<h4>Aims/introduction</h4>Our aims were to examine the add-on effects of a sodium-glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal muscle mass (SMM) negative regulator, myostatin; and a metabolic regulator, irisin, in patients with type 2 diabetes.<h4>Materials and methods</h4>A total of 54 patients with type 2 diabetes were randomly divided into dapagliflozin and control groups. The dapagliflozin group received dapagliflozin 5 mg/day in addition to conventional therapy for 24 weeks. The primary outcome was the change in the level of serum FGF21 from baseline. The secondary outcomes included changes from baseline in a","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2026-07-15T19:18:18.668Z","creation":"2020-05-23T07:13:28Z"},"accession":"S-EPMC7232283","cross_references":{"pubmed":["31721467"],"doi":["10.1111/jdi.13179"]}}